Search

Your search keyword '"Kieback, Arne"' showing total 25 results
Start Over Author "Kieback, Arne"
25 results on '"Kieback, Arne"'

5. German Multicenter Real-World Registry of Stenting for Superficial Femoral Artery Disease: Clinical Results and Predictive Factors for Revascularization

Author

Krankenberg, Hans, Tübler, Thilo, Sixt, Sebastian, Fischer, Matthias, Schmiedel, Rainer, Schulte, Karl-Ludwig, Balzer, Jörn O., Kieback, Arne, Fiehn, Eduard, Wittenberg, Günther, Ali, Tammam, Tiefenbacher, Christiane, Jahnke, Thomas, Steinkamp, Hermann J., Wegscheider, Karl, Treszl, András, Ingwersen, Maja, and Zeller, Thomas

Published
2014
Full Text
View/download PDF

9. One simple claudication question as first step in Peripheral Arterial Disease (PAD) screening: A meta-analysis of the association with reduced Ankle Brachial Index (ABI) in 27,945 subjects

Author

Kieback, Arne Georg, primary, Espinola-Klein, Christine, additional, Lamina, Claudia, additional, Moebus, Susanne, additional, Tiller, Daniel, additional, Lorbeer, Roberto, additional, Schulz, Andreas, additional, Meisinger, Christa, additional, Medenwald, Daniel, additional, Erbel, Raimund, additional, Kluttig, Alexander, additional, Wild, Philipp S., additional, Kronenberg, Florian, additional, Kröger, Knut, additional, Ittermann, Till, additional, and Dörr, Marcus, additional

Published
2019
Full Text
View/download PDF

10. Angiologie: Panta rhei

Author

Gröchenig, Ernst, primary, Groechenig, Ernst, additional, Grumann, Thorsten, additional, Kieback, Arne, additional, Kucher, Nils, additional, and Righini, Marc, additional

Published
2018
Full Text
View/download PDF

15. Association Between Chromosome 9p21 Variants and the Ankle-Brachial Index Identified by a Meta-Analysis of 21 Genome-Wide Association Studies

Author

Murabito, Joanne M., primary, White, Charles C., additional, Kavousi, Maryam, additional, Sun, Yan V., additional, Feitosa, Mary F., additional, Nambi, Vijay, additional, Lamina, Claudia, additional, Schillert, Arne, additional, Coassin, Stefan, additional, Bis, Joshua C., additional, Broer, Linda, additional, Crawford, Dana C., additional, Franceschini, Nora, additional, Frikke-Schmidt, Ruth, additional, Haun, Margot, additional, Holewijn, Suzanne, additional, Huffman, Jennifer E., additional, Hwang, Shih-Jen, additional, Kiechl, Stefan, additional, Kollerits, Barbara, additional, Montasser, May E., additional, Nolte, Ilja M., additional, Rudock, Megan E., additional, Senft, Andrea, additional, Teumer, Alexander, additional, van der Harst, Pim, additional, Vitart, Veronique, additional, Waite, Lindsay L., additional, Wood, Andrew R., additional, Wassel, Christina L., additional, Absher, Devin M., additional, Allison, Matthew A., additional, Amin, Najaf, additional, Arnold, Alice, additional, Asselbergs, Folkert W., additional, Aulchenko, Yurii, additional, Bandinelli, Stefania, additional, Barbalic, Maja, additional, Boban, Mladen, additional, Brown-Gentry, Kristin, additional, Couper, David J., additional, Criqui, Michael H., additional, Dehghan, Abbas, additional, den Heijer, Martin, additional, Dieplinger, Benjamin, additional, Ding, Jingzhong, additional, Dörr, Marcus, additional, Espinola-Klein, Christine, additional, Felix, Stephan B., additional, Ferrucci, Luigi, additional, Folsom, Aaron R., additional, Fraedrich, Gustav, additional, Gibson, Quince, additional, Goodloe, Robert, additional, Gunjaca, Grgo, additional, Haltmayer, Meinhard, additional, Heiss, Gerardo, additional, Hofman, Albert, additional, Kieback, Arne, additional, Kiemeney, Lambertus A., additional, Kolcic, Ivana, additional, Kullo, Iftikhar J., additional, Kritchevsky, Stephen B., additional, Lackner, Karl J., additional, Li, Xiaohui, additional, Lieb, Wolfgang, additional, Lohman, Kurt, additional, Meisinger, Christa, additional, Melzer, David, additional, Mohler, Emile R., additional, Mudnic, Ivana, additional, Mueller, Thomas, additional, Navis, Gerjan, additional, Oberhollenzer, Friedrich, additional, Olin, Jeffrey W., additional, O'Connell, Jeff, additional, O'Donnell, Christopher J., additional, Palmas, Walter, additional, Penninx, Brenda W., additional, Petersmann, Astrid, additional, Polasek, Ozren, additional, Psaty, Bruce M., additional, Rantner, Barbara, additional, Rice, Ken, additional, Rivadeneira, Fernando, additional, Rotter, Jerome I., additional, Seldenrijk, Adrie, additional, Stadler, Marietta, additional, Summerer, Monika, additional, Tanaka, Toshiko, additional, Tybjaerg-Hansen, Anne, additional, Uitterlinden, Andre G., additional, van Gilst, Wiek H., additional, Vermeulen, Sita H., additional, Wild, Sarah H., additional, Wild, Philipp S., additional, Willeit, Johann, additional, Zeller, Tanja, additional, Zemunik, Tatijana, additional, Zgaga, Lina, additional, Assimes, Themistocles L., additional, Blankenberg, Stefan, additional, Boerwinkle, Eric, additional, Campbell, Harry, additional, Cooke, John P., additional, de Graaf, Jacqueline, additional, Herrington, David, additional, Kardia, Sharon L.R., additional, Mitchell, Braxton D., additional, Murray, Anna, additional, Münzel, Thomas, additional, Newman, Anne B., additional, Oostra, Ben A., additional, Rudan, Igor, additional, Shuldiner, Alan R., additional, Snieder, Harold, additional, van Duijn, Cornelia M., additional, Völker, Uwe, additional, Wright, Alan F., additional, Wichmann, H.-Erich, additional, Wilson, James F., additional, Witteman, Jacqueline C.M., additional, Liu, Yongmei, additional, Hayward, Caroline, additional, Borecki, Ingrid B., additional, Ziegler, Andreas, additional, North, Kari E., additional, Cupples, L. Adrienne, additional, and Kronenberg, Florian, additional

Published
2012
Full Text
View/download PDF

16. Abstract 18120: Variants of Toll Like Receptor 4 Have Prognostic Value in Patients with Dilated Cardiomyopathy

Author

Riad, Alexander, primary, Meyer zu Schwabedissen, Henriette, additional, Weitmann, Kerstin, additional, Grube, Markus, additional, Dörr, Marcus, additional, Herda, Lars R, additional, Empen, Klaus, additional, Kieback, Arne, additional, Hummel, Astrid, additional, Kandolf, Reinhard, additional, Hoffmann, Wolfgang, additional, Kroemer, Heyo K, additional, and Felix, Stephan B, additional

Published
2011
Full Text
View/download PDF

22. Distal False Lumen Occlusion in Aortic Dissection With a Homemade Extra-Large Vascular Plug: The Candy-Plug Technique.

Author

KöIbel, Tilo, Lohrenz, Christina, Kieback, Arne, Diener, Holger, Sebastian Debus, Eike, and Larena-Avellaneda, Axel

Abstract

Purpose: To report a technique to create an extra-large vascular plug for occlusion of a large distal false lumen in chronic aortic dissection. Technique: The "candy-plug" technique is demonstrated in a 58-year-old multimorbid man with a history of complicated acute type B aortic dissection and a 9-cm chronic thoracic false lumen aneurysm. The patient underwent a staged repair with a cervical debranching procedure as a first step and a thoracic endovascular aortic repair from the innominate artery to the celiac artery as a second step. To occlude the large false lumen from a distal route, a stent-graft was modified on-table with a diameter-restricting suture, giving it a wrapped candy-like shape. This plug was deplàyed into the false lumen, and the remaining opening was occluded with a standard vascular plug. On 3-month follow-up imaging, the thoracic false lumen aneurysm remained completely thrombosed. Conclusion: The candy-plug technique can facilitate complete occlusion of chronic thoracic false lumen aneurysm by prohibiting distal false lumen backflow. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

23. Acute Hemodynamic Effects of -Blockers in Patients with Severe Congestive Heart Failure Comparison of Celiprolol and Esmolol

Author

Felix, Stephan B., Stangl, Verena, Kieback, Arne, Doerffel, Wolf, Staudt, Alexander, Wernecke, Klaus D., Baumann, Gert, and Stangl, Karl

Abstract

The present study was designed to investigate, in patients with severe heart failure, the dose-dependent acute hemodynamic effects of celiprolol versus those of esmolol. Celiprolol is a 1-receptor blocker with vasodilating properties, whereas esmolol is an ultra-short-acting 1-blocker. Included were 14 patients with decompensated chronic heart failure (NYHA class IV) due to coronary heart disease (n 8) or to dilated cardiomyopathy (n 6). Each patient received both celiprolol and esmolol in random fashion. The -blockers were administered in four dose tiers, with an increase in dosage every 15 min. Hemodynamic measurements were obtained with a Swan–Ganz thermodilution catheter. Administration of celiprolol (5, 10, 20, and 50 g/kg) took place intravenously. After intravenous administration of a loading dose of 500 g/kg, we continuously infused esmolol at increasing doses, which were individually titrated for each patient. Mean infusion rates of esmolol were as follows 40, 75, 140, and 230 mol/kg per minute. Celiprolol and esmolol induced a comparable dose-dependent decrease in heart rate to a minimum of −10 below baseline. Esmolol caused a significant dose-dependent decrease (−25 below baseline at the highest dose level) in cardiac index (CI). After administration of celiprolol, CI decreased only transiently (−10 below baseline at the second and third dose level) and did not differ from the baseline at the highest dose level. For treatment of severe heart failure, initiation of intravenous -blocker therapy with low doses of a 1-blocker with vasodilating effects may have hemodynamic advantages over conventional -blockade.

Published
2001

24. Claudication, in contrast to angina pectoris, independently predicts mortality risk in the general population.

Author

Kieback AG, Lorbeer R, Wallaschofski H, Ittermann T, Völzke H, Felix S, and Dörr M

Subjects
Adult, Aged, Female, Germany epidemiology, Health Surveys, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Prognosis, Proportional Hazards Models, Risk Assessment, Risk Factors, Surveys and Questionnaires, Time Factors, Angina Pectoris mortality, Intermittent Claudication mortality
Abstract

Background: The aim of our analyses was to investigate whether claudication and angina pectoris, each defined and based on the answer to a single question, are predictive of future mortality., Probands and Methods: The study population consisted of 3995 subjects selected from the population-based Study of Health In Pomerania (SHIP). Kaplan-Meier analysis and multivariable Cox proportional hazards regression analysis were used to analyze the association of angina pectoris and claudication with all-cause and cardiovascular mortality adjusted for major cardiovascular risk factors., Results: At baseline, 417 individuals had symptoms of angina pectoris, and 323 had symptoms of claudication. During a median follow-up of 8.5 years, 277 individuals died. Individuals with claudication had a higher fully-adjusted all-cause mortality rate (Hazard Ratio (HR) 1.79; 95 % CI 1.34, 2.39, p < 0.001) and a higher sex- and age-adjusted cardiovascular mortality rate (HR 1.76; 95 % CI 1.03, 2.99, p = 0.038) compared to subjects without claudication. In contrast, subjects with angina pectoris had neither an elevated fully-adjusted all-cause mortality rate (HR 1.15; 95 % CI 0.82, 1.61, p = 0.413) nor sex- and age-adjusted cardiovascular mortality rate (HR 0.71; 95 % CI 0.34, 1.48, p = 0.363) compared to those without this symptom., Conclusions: Claudication, in contrast to angina pectoris, is a strong, independent predictor of all-cause mortality.

Published
2012
Full Text
View/download PDF

25. Hemodynamic effects of alpha1-adrenoceptor antagonist, doxazosin, in patients with chronic congestive heart failure.

Author

Kieback AG, Rödiger O, Jaenecke H, Grohmann A, Wernecke KD, Baumann G, and Felix SB

Subjects
Adrenergic alpha-Antagonists adverse effects, Aged, Chronic Disease, Double-Blind Method, Doxazosin adverse effects, Electrocardiography, Female, Heart Failure diagnosis, Heart Failure physiopathology, Heart Rate drug effects, Hemodynamics drug effects, Humans, Hypotension chemically induced, Male, Middle Aged, Pulmonary Wedge Pressure drug effects, Radiography, Thoracic, Stroke Volume drug effects, Time Factors, Treatment Outcome, Vascular Resistance drug effects, Adrenergic alpha-Antagonists therapeutic use, Doxazosin therapeutic use, Heart Failure drug therapy
Abstract

Purpose: Non-selective alpha-adrenoceptor antagonists have not demonstrated significant beneficial effects in chronic heart failure. Previous studies with the selective alpha1-adrenoceptor antagonist, doxazosin, led to conflicting results. We assessed the hypothesis that treatment with doxazosin adjuvant to standard oral therapy results in significant increase in cardiac index in patients with chronic heart failure., Methods: A double-blind, randomized study was conducted on 30 patients with chronic congestive heart failure (NYHA III-IV), with cardiac index<2.5 l/minxm, and/or with pulmonary capillary wedge pressure>16 mm Hg. Of the 30 patients, 15 were treated with doxazosin and 15 with placebo, both adjuvant to stable oral therapy, which included a minimum of an ACE inhibitor and a diuretic. Hemodynamic measurements were performed on days 1 and 2, and after 12 weeks on study medication. On day 1, patients were treated with 4 mg doxazosin or placebo. On day 2 and throughout the following 12 weeks, the patients were treated with 4 mg or 8 mg doxazosin/d (the latter, if 4 mg/d did not induce an increase >0.75 l/minxm in cardiac index), or with placebo., Results: Six patients were treated with 4 mg doxazosin/d (group A), 9 patients with 8 mg doxazosin/d (group B), and 15 with placebo. Baseline values for the cardiac index on day 1, day 2, and after 12 weeks failed to disclose significant differences between patient groups and between the days of study. On day 1, the increase in cardiac index compared with baseline was significantly higher in group A than in the placebo group (P=0.004) and group B (P=0.001). On day 2, the increase in cardiac index compared with baseline on day 1 was significantly higher in group A than in group B (P=0.003) (with reference to alpha/3=0.0167 according to Bonferroni). This was no longer observed after 12 weeks. In the placebo group, following significant changes occurred in baseline values, heart rate was lower (P=0.023) and stroke volume index was higher after 12 weeks in comparison to day 1 (P=0.032)., Conclusions: In conclusion, oral application of doxazosin supplementary to standard oral medication did not induce sustained hemodynamic benefit. Significant acute increase in cardiac index was observed in a minority (40%) of patients, whereas favorable changes in baseline hemodynamic parameters after 12 weeks occurred in the placebo group.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results